Prediction of residual liver hypertrophy by liver iodine map

Study on liver iodine map by portal vein angiography and prediction of expected residual hepatic hypertrophy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041210088

Enrollment

199

Registered

2021-10-22

Start date

2021-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary or metastatic liver cancer or biliary tract cancer Liver cancer, biliary tract cancer

Interventions

Two dual enrgy CT scans, simple CT and contrast CT, during portal vein embolization

D003287, D015898

iodine contrast media, X-ray exposure

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with primary or metastatic liver cancer or biliary tract cancer who are scheduled for extended hepatectomy and will undergo portal vein embolization Written consent must be obtained.

Exclusion criteria

Exclusion criteria: contraindicated patients for iodine contrast administration Decreased renal function (eGFR less than 30 mL/min/1.73m2)

Design outcomes

Primary

Measure	Time frame
Liver volumes of embolized and unembolized lobes and their rates of change before and after portal vein embolization	—

Secondary

Measure	Time frame
Complications due to portal vein embolization (e.g., liver dysfunction and portal vein thrombus), presence of liver failure after extended hepatectomy, length of hospital stay, and survival	—

Contacts

Public ContactTomohiro Komada

Nagoya university hospital

tidai@med.nagoya-u.ac.jp+81-52-744-2327

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026